What the 2026 EU MDR Post-Market Surveillance Rules Mean for Your Anti-Snoring Device
EU MDR post-market surveillance rules for sleep devices bring mandatory EUDAMED registration and faster incident reporting
A plain-language guide to what tightened EU safety monitoring, EUDAMED registration, and faster incident reporting mean for the anti-snoring or sleep device already on your nightstand.
Why EU MDR post-market surveillance rules matter for your sleep devices in 2026
EU MDR post-market surveillance rules for sleep devices changed in a real, practical way in 2026, and the shift touches anyone who owns or is shopping for a CE-marked anti-snoring or sleep device. Post-market surveillance (PMS) is the system manufacturers use to keep collecting safety data after a product reaches the market, not just before it launches. Under the EU Medical Device Regulation (Regulation (EU) 2017/745), every CE-marked device sold in Europe — from a CE-certified Class I nasal stent to a Class III implant — now feeds into a stricter, more traceable monitoring system.
For someone managing snoring or mild-to-moderate obstructive sleep apnea (OSA), this matters because it gives you a concrete way to judge whether a device is genuinely safe and accountable. It is not just paperwork for regulators. It is the mechanism that catches faulty batches, tracks complaints, and forces a manufacturer to act if a pattern of harm appears.
Snoring and sleep-apnea devices sit in a wide range of risk categories, from a soft silicone stent worn in the nose to a powered CPAP machine with a motor, hose, and mask. The new post-market rules do not treat every device the same way, but every device now belongs to the same traceable system, which is the biggest practical change for everyday buyers.
- Post-market surveillance is the ongoing safety-monitoring system every CE-marked device must maintain after it reaches consumers.
- 2026 brought two hard deadlines: mandatory EUDAMED modules from 28 May 2026, and full registration of already-marketed devices by 28 November 2026.
- The rules apply the same way to a simple nasal stent as to a complex CPAP machine, though the paperwork scales with risk class.
How EU MDR post-market surveillance rules for sleep devices actually work
EU MDR post-market surveillance works through a chain of documents and databases that follow a device from manufacture to the moment it stops being used. Manufacturers must run a formal PMS system, described in a PMS plan, that defines how they collect complaints, incident reports, and field data. That data then rolls up into one of two report types, depending on how risky the device is considered.
Class I devices, the lowest-risk category that includes most simple nasal dilators and stents, require a Post-Market Surveillance Report (PMSR) under MDR Article 85. Higher-risk devices — Class IIa, IIb, and III, which cover things like CPAP therapy machines, oral appliances with electronic components, and implants — require a Periodic Safety Update Report (PSUR) under Article 86 instead, reviewed by an independent notified body. The table below breaks down how the two differ.
| Device class | Report required | Update frequency | Typical sleep-device example |
|---|---|---|---|
| Class I | PMSR (Article 85) | Kept current, reviewed on request | Nasal stent or dilator, e.g. Back2Sleep |
| Class IIa | PSUR (Article 86) | At least every 2 years | Custom oral advancement device |
| Class IIb | PSUR (Article 86), notified-body reviewed | At least annually | CPAP or respiratory therapy machine |
| Class III | PSUR (Article 86), notified-body reviewed | At least annually | Implantable airway device |
Two more terms are worth knowing. Post-Market Clinical Follow-Up (PMCF) is the ongoing collection of real-world clinical data, used to confirm a device still performs as claimed years after approval. The Summary of Safety and Clinical Performance (SSCP), required for higher-risk devices, is a public-facing document that translates the technical file into language a patient or clinician can actually read.
What EUDAMED is and why the 2026 deadlines matter
EUDAMED is the European Database on Medical Devices, the central registry where every CE-marked device, manufacturer, and safety incident in the EU is meant to be logged in one searchable place. Before 2026, large parts of EUDAMED were optional or still being built, which meant a lot of post-market data lived in scattered national systems instead of one shared database.
That changed this year. According to the European Commission's Public Health directorate and MedTech Europe, EUDAMED's first four modules — Actor Registration, UDI/Device Registration, Notified Bodies and Certificates, and Market Surveillance — became legally mandatory for all EU economic operators from 28 May 2026. Devices already on the market before that date get a grace period, but they must be fully registered by 28 November 2026.
Before this rollout, a complaint filed about a device in France did not automatically connect to a similar complaint filed in Germany or Spain, which slowed down how quickly a real safety pattern could be spotted. A single mandatory database closes that gap, so a cluster of incidents anywhere in the EU becomes visible to every national regulator at once.
In practice, this means every legitimately CE-marked sleep or snoring device should soon carry a Unique Device Identifier (UDI) that you, in theory, can trace back to a registered manufacturer and a valid certificate inside EUDAMED. That traceability is the entire point of the 2026 rollout.
The incident-reporting clock that protects you as a user
MDR Article 87 sets strict deadlines for how fast a manufacturer must tell regulators about a safety problem once they become aware of it. These timelines did not disappear with the 2026 EUDAMED rollout — they now run through it, which makes enforcement faster and more visible across all 27 member states at once.
1Serious public health threats
A manufacturer must notify the relevant authority within just 2 calendar days of becoming aware of an issue that could pose an immediate public health risk.
2Death or unanticipated serious deterioration
Cases involving a death or an unexpected, serious worsening of a patient's health must be reported within 10 calendar days.
3Other serious incidents
All other serious incidents, such as a device malfunction that could have caused harm, must be reported within 15 calendar days of the manufacturer learning about it.
- Under MDR Article 87, the reporting clock runs on just 2, 10, or 15 days depending on severity, not months.
- These reports now flow into EUDAMED's Market Surveillance module, giving regulators a shared, real-time view across the EU.
- A device with no clear manufacturer contact or traceable UDI cannot realistically be held to this clock.
What prompted the EU to tighten post-market vigilance in the first place
Tightened post-market rules are not an abstract regulatory exercise. One of the clearest examples sits in the EU's own history: the 2010 discovery that Poly Implant Prothèse (PIP) breast implants had been filled for years with unauthorized industrial-grade silicone rather than approved medical-grade material. The scandal affected an estimated 300,000 to 400,000 women worldwide, according to French and European health authorities, and it became one of the most-cited reasons the EU eventually replaced its older device directives with the stricter Medical Device Regulation described throughout this article.
The EU's answer to this kind of risk is precisely the system described above: mandatory PMS plans, faster incident reporting, and a central EUDAMED registry that lets a problem surface once across all 27 member states, instead of being buried in fragmented national reports. A device that cannot demonstrate this chain of accountability is a device you should be cautious about.
How to check whether your snoring or sleep device is genuinely CE compliant
Verifying a device takes a few minutes and does not require any technical background. Here is the practical sequence to follow before you trust or buy a snoring or sleep device.
1Find the CE mark and device class on the packaging or IFU
Every legitimate device lists its CE mark and risk class (I, IIa, IIb, or III) in the Instructions for Use (IFU) and usually on the outer packaging.
2Locate the UDI code
The Unique Device Identifier is printed on the packaging, often as a barcode with a UDI-DI (device identifier) portion you can search.
3Search the manufacturer and device in EUDAMED
Once fully populated, EUDAMED's public search should let you confirm the manufacturer is registered and the device certificate is active, not expired or withdrawn.
4Check for a real Instructions for Use and safety contact
A compliant manufacturer publishes a downloadable IFU and a clear way to report a problem, which is the front end of their PMS system.
Where Back2Sleep fits in this compliance picture
Back2Sleep is a French, CE-certified Class I medical device, a soft silicone intranasal stent designed to keep the nasal airway open during sleep. Because it sits in the Class I risk category, its manufacturer files a PMSR rather than the heavier PSUR required for CPAP-class devices, and it must have its UDI fully registered in EUDAMED ahead of the 28 November 2026 deadline for already-marketed products.
In practice, that means a buyer can ask the same four questions above about Back2Sleep and get clear answers: a listed CE Class I mark, a traceable UDI, a public IFU, and a defined channel for reporting an issue. Readers who want the underlying evidence behind the device's classification can review the published clinical research on Back2Sleep directly.
- Class I devices file a lighter PMSR, but they are not exempt from EUDAMED registration or the incident-reporting clock.
- Traceability, not device class alone, is what should reassure a buyer.
- Severe OSA still requires medically supervised treatment, whatever risk class the device carries.
A practical buyer's checklist before you trust any anti-snoring device
Post-market surveillance rules give you, the buyer, a short and usable checklist rather than a wall of regulation to decode. Growth in this category makes the checklist more relevant every year: the European anti-snoring devices market is projected to roughly double in size between 2026 and 2034, according to a 2026 MarketDataForecast report, meaning more products and more variation in compliance quality are entering the market.
| Checklist item | Why it matters | Where to look |
|---|---|---|
| Visible CE mark and stated risk class | Confirms the device underwent conformity assessment | Packaging or product page |
| Traceable UDI code | Lets the device be tracked and recalled if needed | Packaging barcode, EUDAMED |
| Registered manufacturer name and address | Confirms someone is legally accountable | IFU, EUDAMED Actor Registration |
| Published Instructions for Use | Shows intended use, limits, and warnings clearly | Manufacturer website |
| Clear incident-reporting contact | Confirms the manufacturer's PMS system is active | Manufacturer website or IFU |
This checklist works for any device category, whether it is a nasal stent, an external adhesive nasal strip, or a mandibular repositioning device. If a seller cannot answer these five points, treat that as a warning sign rather than a technicality.
Watch for a few specific red flags too. A missing or vague CE mark, a UDI that does not appear on packaging at all, stock photos instead of a real device page, or a refusal to share an IFU are all signs a product may be skirting the exact rules this article describes. None of these checks take more than a couple of minutes, and they apply equally whether you are comparing a nasal stent, an external adhesive nasal strip, or a full CPAP setup.
What comes next for EU MDR post-market surveillance and sleep devices
The 2026 EUDAMED rollout is not the finish line. Enforcement will likely tighten further as national authorities gain full visibility into the Market Surveillance module, and post-market clinical follow-up expectations are expected to grow alongside broader updates to sleep-medicine practice, including the 2026 ERS sleep apnea guideline updates that reshaped how clinicians assess OSA severity. Together, these changes push the entire sleep-device category toward more transparency, not less.
For now, the most useful thing a reader can do is treat CE class, UDI traceability, and manufacturer transparency as non-negotiable when evaluating any anti-snoring or sleep device, rather than assuming a CE logo alone tells the whole story.
What Back2Sleep Users Say
Frequently Asked Questions
What does post-market surveillance mean for a medical device?
Post-market surveillance is the ongoing system a manufacturer must run after a device reaches the market, collecting complaints, incident reports, and real-world data to confirm the device stays safe. Under EU MDR, every CE-marked device, including sleep and snoring devices, must feed into this system for as long as it stays on sale.
What is the difference between a PSUR and a PMSR under EU MDR?
A PMSR (Post-Market Surveillance Report) is the lighter document Class I device manufacturers keep current under MDR Article 85. A PSUR (Periodic Safety Update Report) is required for higher-risk Class IIa, IIb, and III devices under Article 86, reviewed by a notified body at least every one to two years.
What is EUDAMED and why does it matter to patients?
EUDAMED is the EU's central database for medical devices, manufacturers, certificates, and safety incidents. For patients, it matters because it lets you trace a device's UDI back to a registered manufacturer and an active CE certificate, instead of relying on packaging claims alone.
When does EUDAMED become mandatory in 2026?
EUDAMED's first four modules, covering actor registration, device and UDI registration, notified bodies and certificates, and market surveillance, became legally mandatory across the EU from 28 May 2026. Devices already on the market must be fully registered in the system by 28 November 2026.
How do I check if my snoring or CPAP device is genuinely CE certified?
Look for a CE mark and stated risk class on the packaging or Instructions for Use, then find the printed UDI code. Once EUDAMED's public search is fully populated, you can search that UDI to confirm the manufacturer is registered and the certificate is active, not expired.
How quickly must a manufacturer report a safety incident under EU MDR?
Under MDR Article 87, manufacturers must report serious public health threats within 2 calendar days, deaths or unexpected serious deterioration within 10 days, and other serious incidents within 15 days of becoming aware of them. These timelines now feed directly into EUDAMED's Market Surveillance module.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.